Background {#Sec1}
==========

Risk adjustment is an important component in clinical epidemiology and health services research using administrative databases, but its methods remain controversial. Administrative databases are widely used in studies because of their availability and large sample sizes, and risk-adjusted mortality is employed as one of the outcome measures. However, the validity of risk-adjustment models for administrative data has been questioned repeatedly \[[@CR1]--[@CR4]\]. It has been argued that administrative data lack important clinical information \[[@CR5]--[@CR8]\] and often do not make distinctions between conditions present on admission and complications occurring during hospitalization \[[@CR6]--[@CR10]\]. Inadequate risk adjustment can lead to misleading consequences such as confounding by indications and low rating of facilities that care for sicker patients. Thus, appropriate risk-adjustment models are desired.

Previous studies have shown that the performance of risk-adjustment models using administrative databases improves when detailed clinical information is added. In addition to patients' demographic characteristics, comorbid illnesses recorded in administrative data enabled risk adjustment using measures such as the Charlson comorbidity index (CCI) \[[@CR11]\]. Furthermore, models using laboratory data, vital signs, and other clinical findings provided better predictions of mortality \[[@CR12]--[@CR15]\], and models using disease-specific diagnostic tests and treatments have been introduced for some diseases \[[@CR16]--[@CR19]\]. Meanwhile, precise laboratory and clinical data are not available in most administrative databases. Therefore, an alternative method has been reported, in which surgeries and major therapeutic procedures are associated with in-hospital death \[[@CR20]\].

In addition to major therapeutic procedures, commonly performed procedures, diagnostic or therapeutic, can reflect the severity of patients on admission. For example, patients who receive oxygen therapy are expected to be in a severe condition compared with those who do not. However, there have been no evaluations of risk-adjustment models that use commonly performed procedures. In addition, previous models using laboratory and clinical data were developed and validated in limited regions.

The aims of the present study were to develop an index of severity using procedure records in a nationwide database, and to examine the ability of this index to predict in-hospital death.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

The Diagnosis Procedure Combination database is a national administrative database of acute-care inpatients in Japan that is linked with a payment system. The mandatory-participating academic hospitals (all 82 hospitals) and voluntary-participating community hospitals provide claims data of all of their acute-care inpatients. In 2012, there were approximately 1,000 participating hospitals with 7 million admissions recorded annually, representing 50 % of all acute-care hospitalizations in Japan.

The database includes the following data: hospital identification code; patient demographics; diagnoses; admission and discharge status; surgeries and procedures performed; drugs used; and special reimbursements for specific conditions. Up to 12 diagnoses for each admission are recorded, and coded using the *International Classification of Diseases,* Tenth Revision (ICD-10). One diagnosis each is recorded for "main diagnosis," "admission-precipitating diagnosis," "most resource-consuming diagnosis," and "second most resource-consuming diagnosis." A maximum of four diagnoses each are recorded for "comorbidities present on admission" and "conditions arising after admission." Suspected diagnoses are allowed to be recorded, in which case they are designated as such. Surgeries, drugs, procedures, and special reimbursements are coded according to the Japanese fee schedule for reimbursement \[[@CR21]\], and their dates of use or application are recorded. The daily quantities of each drug administered are also recorded.

Study cohort {#Sec4}
------------

We included all adult patients (≥18 years) discharged between 1 April 2012 and 31 March 2013 with a confirmed admission-precipitating diagnosis of acute myocardial infarction, congestive heart failure, acute cerebrovascular disease, gastrointestinal hemorrhage, pneumonia, or septicemia. The identification of these six diseases was based on the Classifications Software for Mortality Reporting developed by the Healthcare Cost and Utilization Project \[[@CR22]\], and the following Classifications Software categories were used for the six diseases, respectively: 100, 108, 109, 153, 122, and 2. For congestive heart failure, we also included hypertensive heart disease with heart failure (ICD-10 code: I11.0, I13.0, or I13.2). We excluded the following patients based on their information on the day of admission: those who were admitted to intensive care unit (including coronary care unit); and those who received cardiopulmonary life support (cardiopulmonary resuscitation, electrical cardioversion, cardiopulmonary bypass, extracorporeal membrane oxygenation, or ventricular assist device). We identified the former using reimbursement information, and the latter using procedure information.

The data for diagnostic and therapeutic procedures performed on the day of admission, use of catecholamines (epinephrine, norepinephrine, dopamine, and dobutamine) and vasopressin on the day of admission, and use of blood transfusions (red blood cells, platelets, fresh frozen plasma, and albumin) on the day of admission were extracted. A list of the procedures and codes examined in this study is shown in the Additional file 1. For the examinations, examples of the tested items are also listed. Patients who underwent at least one procedure categorized under a given code were assigned that specific code. For example, "D007, blood chemistry tests" would be coded for patients who underwent creatinine testing, as well as for patients who underwent sodium, potassium, and chloride testing. Comorbidities were examined using the diagnoses recorded as comorbidities present on admission, and CCI values were calculated using the coding algorithm \[[@CR23]\] and weight assignment \[[@CR24]\] reported by Quan et al.

We randomly assigned the eligible patients to the derivation cohort or validation cohort. We developed the severity index for inpatients using the derivation cohort, and tested its performance in the validation cohort.

Index development {#Sec5}
-----------------

In the derivation cohort, we first examined the proportion of patients who underwent each procedure (including use of catecholamines and vasopressin) on the day of admission. For each procedure with ≥1 % prevalence, the chi-square test was used to evaluate the association with in-hospital death. The procedures positively associated with in-hospital death (*P* \< 0.1) were retained for further analysis. Procedures with a correlation (phi coefficient \>0.6) were managed in the following manner: (i) a group of procedures usually performed simultaneously were combined into a single variable as at least one procedure; and (ii) for a group of procedures performed consecutively, only the procedure usually performed first was retained. Subsequently, a logistic regression model was developed with in-hospital death as the outcome variable. In the model, the admission-precipitating diagnosis, age, sex, and CCI were included as categorical covariates (age categories: \<60, 60--69, 70--79, 80--89, ≥90; CCI categories: 0, 1, 2, ≥3) in addition to the procedures.

Using the statistically significant (*P* \< 0.05) regression coefficients obtained with the model, we derived an index-calculating formula by the method of Sullivan et al. \[[@CR25]\], using CCI = 1 as a reference. Specifically, a point was assigned to each procedure so that it equaled the integer nearest to the quotient of the regression coefficient for the procedure divided by the regression coefficient for CCI = 1. Thus, the points for each procedure were derived to represent the effect on death relative to the CCI. The severity index for each patient could then be calculated as the sum of the points assigned to the procedures performed on the patient.

Index validation {#Sec6}
----------------

The severity index was calculated for patients in the validation cohort. We examined the distribution of its values, and used a logistic regression model with the index as a continuous variable (model 1) to examine its association with in-hospital death. For every value, the expected death rate among patients with the value was compared with the observed death rate.

We then constructed multiple logistic regression models with different independent variables: severity index, diagnosis, age, and sex (model 2); diagnosis, age, sex, and CCI (model 3); severity index, diagnosis, age, sex, and CCI (model 4). The discriminatory abilities of the different models were assessed using the *c*-statistics. We used the integrated discrimination improvement (IDI) \[[@CR26]\] to evaluate the improvement of model discrimination by adding the severity index. The IDI is a difference in the discrimination slope (difference between the mean predicted probability of an event for those with events and the corresponding mean predicted probability of an event for those without events) between two models and is a measure of the improvement in model performance. In this study, the IDI was calculated for a comparison of model 4 with model 3.

We evaluated the relative contribution of the severity index to the prediction of death using the *ω*-statistic \[[@CR27]\]. The *ω*-statistic is the ratio of the variances of the contributions of two groups of variables to the log-odds of the outcome in a logistic regression model. In this study, we used model 4, and compared the relative contribution of the severity index with that of four other variables. In addition, the calibration of model 4 was evaluated using the Hosmer--Lemeshow decile partition.

We conducted further analyses to test the performance of the severity index across various subgroups of patients. Using the severity index derived from all patients in the derivation cohort, model 4 was constructed for the following subgroups of the validation cohort: those who arrived in an ambulance and those who did not; those who were referred by another institution and those with no referral. We also built models for each admission-precipitating diagnosis, with severity index, age, sex, and CCI as independent variables. The model discrimination and calibration were evaluated for each subgroup.

The *P* values were 2 sided. Statistical analyses were performed using IBM SPSS for Windows, version 22.0 (IBM Corp., Armonk, NY, USA). Because of the anonymous nature of the data, the need for informed consent was waived. Study approval was obtained from the Institutional Review Board of The University of Tokyo.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

We identified 604,579 adult patients with one of the six diseases as the admission-precipitating diagnosis during the study period. Of these patients, 65,194 were excluded because of intensive care unit admission (*n* = 59,995) or cardiopulmonary life support (*n* = 7,019) on the day of admission, leaving 539,385 patients for analysis. For these patients, the mean age was 74.1 years, 57.5 % were male, and the in-hospital mortality rate was 9.5 %. The background characteristics of all patients, patients assigned to the derivation cohort (*n* = 270,054), and patients assigned to the validation cohort (*n* = 269,331) are presented in Table [1](#Tab1){ref-type="table"}. The characteristics were similar between the two cohorts.Table 1Characteristics of patients included in the studyDerivation cohortValidation cohortAll patientsTotal number270 054269 331539 385Admission-precipitating diagnosis, n (%)  Acute myocardial infarction10 421 (3.9)10 176 (3.8)20 597 (3.8)  Congestive heart failure56 970 (21.1)56 927 (21.1)113 897 (21.1)  Acute cerebrovascular disease89 983 (33.3)90 071 (33.4)180 054 (33.4)  Gastrointestinal hemorrhage35 073 (13.0)34 429 (12.8)69 502 (12.9)  Pneumonia68 387 (25.3)68 386 (25.4)136 773 (25.4)  Septicemia9220 (3.4)9342 (3.5)18 562 (3.4)Male, n (%)155 273 (57.5)154 857 (57.5)310 130 (57.5)Age, mean (SD)74.1 (14.2)74.1 (14.2)74.1 (14.2)Age by category, n (%)  \<6037 363 (13.8)37 425 (13.9)74 788 (13.9)  60--6947 235 (17.5)46 833 (17.4)94 068 (17.4)  70--7973 468 (27.2)73 509 (27.3)146 977 (27.2)  80--8984 965 (31.5)84 964 (31.5)169 929 (31.5)  ≥9027 023 (10.0)26 600 (9.9)53 623 (9.9)Charlson comorbidity index, n (%)  0162 038 (60.0)161 597 (60.0)323 635 (60.0)  134 307 (12.7)34 015 (12.6)68 322 (12.7)  252 841 (19.6)52 688 (19.6)105 529 (19.6)  ≥320 868 (7.7)21 031 (7.8)41 899 (7.8)In-hospital death, n (%)25 638 (9.5)25 449 (9.4)51 087 (9.5)Length of stay in days, median (IQR)15 (9--29)15 (9--29)15 (9--29)IQR -- interquartile rangeSD -- standard deviation

Index development {#Sec9}
-----------------

There were 38 procedures with ≥1 % prevalence in the derivation cohort. Their rate of use in the surviving and deceased patients, and the results of chi-square tests are presented in Table [2](#Tab2){ref-type="table"}. Of the 28 procedures significantly associated with in-hospital death, 11 were correlated with each other in five groups. The three blood examinations (blood chemistry, hematology, plasma protein immunology), two urine examinations (general urine test, urine microscopy), and two microbiological examinations (bacterial microscopy, bacterial culture) were combined as blood tests (excluding coagulation), urinalyses (excluding chemistry), and bacterial microscopy or culture, respectively. Thus, for example, "blood tests (excluding coagulation)" would be counted for patients who underwent sodium, potassium, and hemoglobin testing, as well as for patients who underwent C-reactive protein testing. Central venous infusion and oxygen administration were respectively correlated with central venous catheter insertion and pulse oximetry, which logically precede each procedure. Therefore, central venous catheter insertion and pulse oximetry were retained, while central venous infusion and oxygen administration were excluded from the analysis. The 22 candidate variables were then entered into a logistic regression model, the results of which are presented in Table [3](#Tab3){ref-type="table"}. There were seven procedure variables significantly associated with decreased risk of death, and twelve procedure variables significantly associated with increased risk of death. Because CCI = 1 was not significantly associated with increased odds of death, we divided the regression coefficient for CCI = 2 (0.182) by two to obtain an estimate for the coefficient for CCI = 1 and used it as a reference. The points assigned to each procedure are also presented in Table [3](#Tab3){ref-type="table"}.Table 2Procedures with ≥1 % prevalence in the derivation cohortSurviving patients (n = 244 416)Deceased patients (n = 25 638)*P* value^a^%(n)%(n)Blood chemistry tests87.2(213 046)89.5(22 949)\<0.001Hematology tests86.1(210 402)88.6(22 704)\<0.001Plasma protein immunology tests^b^81.0(198 064)85.4(21 896)\<0.001Radiography78.1(190 981)81.6(20 922)\<0.001Electrocardiogram69.3(169 490)69.7(17 869)0.244\#Peripheral intravenous infusion65.1(159 043)72.5(18 581)\<0.001Coagulation tests59.5(145 418)62.2(15 937)\<0.001Computed tomography scan50.6(123 559)62.2(15 938)\<0.001Infectious disease immunology tests^c^50.5(123 481)49.2(12 622)\<0.001†Hepatitis virus tests39.5(96 552)37.8(9681)\<0.001†Heart rate/respiration monitoring37.4(91 457)49.8(12 770)\<0.001Pulse oximetry34.9(85 254)51.2(13 128)\<0.001Oxygen administration30.5(74 526)54.5(13 961)\<0.001Urine tests (general)32.0(78 225)35.3(9046)\<0.001Endocrinology tests28.3(69 282)32.1(8222)\<0.001Bacterial culture25.0(61 069)34.5(8852)\<0.001Urine microscopy21.6(52 891)24.2(6211)\<0.001Immunohematology tests^d^21.8(53 197)21.4(5486)0.175\#Bacterial microscopy20.1(49 180)27.8(7127)\<0.001Urinary catheter insertion18.0(43 933)37.2(9534)\<0.001Ultrasound imaging18.9(46 118)18.8(4830)0.909\#Magnetic resonance imaging18.6(45 489)10.2(2615)\<0.001†Acid-fast bacilli culture8.5(20 879)10.6(2727)\<0.001Bacterial drug susceptibility tests7.2(17 667)12.7(3267)\<0.001Sputum suction5.3(13 061)22.2(5680)\<0.001Use of catecholamines or vasopressin5.1(12 371)12.3(3143)\<0.001Red blood cell transfusion5.0(12 268)5.2(1324)0.313\#Nucleic acid amplification tests3.7(9102)4.6(1178)\<0.001Tumor markers3.3(8018)2.6(667)\<0.001†Invasive arterial pressure measurement2.3(5649)4.4(1130)\<0.001Autoantibody tests2.3(5740)1.9(488)\<0.001†Urine chemistry tests2.1(5130)2.6(654)\<0.001Gastric drainage tube insertion1.6(3993)6.1(1559)\<0.001Central venous catheter insertion1.2(2997)5.3(1346)\<0.001Intratracheal intubation0.9(2252)7.7(1963)\<0.001Stool tests1.4(3377)1.2(311)0.027†Central venous infusion1.0(2467)4.5(1163)\<0.001Temporary urinary catheterization1.0(2465)1.4(352)\<0.001^a^The *P* values were obtained by the chi-square test for in-hospital death^b^For example, C-reactive protein, complement activity^c^For example, viral antibody tests, β-D-glucan assay^d^For example, blood type test, Coombs test\# Not significant† Significantly associated with decreased risk of deathTable 3Result of logistic regression analysis in the derivation cohort and points assigned to each procedureVariableβexp(β)95 % CI*P* valuePoints for procedureAdmission-precipitating diagnosis  Acute myocardial infarctionRef  Congestive heart failure−0.100.900.83 -- 0.980.012  Acute cerebrovascular disease−0.110.900.82 -- 0.970.010  Gastrointestinal hemorrhage−0.510.600.55 -- 0.66\<0.001  Pneumonia0.041.040.95 -- 1.130.405  Septicemia0.732.071.87 -- 2.28\<0.001Sex (female)−0.120.890.86 -- 0.91\<0.001Age  \<60Ref  60--690.351.431.33 -- 1.53\<0.001  70--790.681.981.86 -- 2.11\<0.001  80--891.143.122.94 -- 3.31\<0.001  ≥901.604.964.65 -- 5.30\<0.001Charlson comorbidity index  0Ref  10.031.030.98 -- 1.070.233  20.181.201.16 -- 1.24\<0.001  ≥30.722.051.96 -- 2.14\<0.001Procedure  Invasive arterial pressure measurement−0.300.740.68 -- 0.81\<0.001−3  Blood tests (excluding coagulation)−0.260.770.73 -- 0.81\<0.001−3  Radiography−0.200.820.79 -- 0.86\<0.001−2  Urinalyses (excluding chemistry)−0.180.840.81 -- 0.87\<0.001−2  Temporary urinary catheterization−0.180.840.74 -- 0.940.004−1  Endocrinology tests−0.060.940.91 -- 0.97\<0.001−1  Bacterial microscopy or culture−0.050.950.91 -- 0.990.019−1  Acid-fast bacilli culture−0.040.960.91 -- 1.020.206\#  Coagulation tests−0.030.970.94 -- 1.010.117\#  Nucleic acid amplification tests0.011.010.93 -- 1.090.842\#  Bacterial drug susceptibility tests0.061.061.01 -- 1.120.0221  Urine chemistry tests0.101.101.00 -- 1.210.0411  Heart rate/respiration monitoring0.181.201.16 -- 1.24\<0.0012  Peripheral intravenous infusion0.181.201.16 -- 1.24\<0.0012  Computed tomography scan0.251.281.24 -- 1.32\<0.0013  Pulse oximetry0.291.331.29 -- 1.37\<0.0013  Gastric drainage tube insertion0.321.381.27 -- 1.50\<0.0014  Urinary catheter insertion0.471.601.55 -- 1.66\<0.0015  Central venous catheter insertion0.491.631.49 -- 1.77\<0.0015  Use of catecholamines or vasopressin0.702.021.92 -- 2.13\<0.0018  Sputum suction1.113.042.92 -- 3.16\<0.00112  Intratracheal intubation2.057.777.14 -- 8.45\<0.00123\# No points assigned because of non-significance of the coefficientCI -- confidence interval

Index performance {#Sec10}
-----------------

The severity index calculated for patients in the validation cohort ranged from −12 to 62, with a mean of 2.13 (standard deviation: 6.85). The distribution of the index values in the validation cohort is presented in Fig. [1](#Fig1){ref-type="fig"}. The values with small numbers of patients were grouped to include at least 1 % of the patients. The observed death rates for the values and their 95 % confidence intervals (CI) and the expected death rates are also presented.Fig. 1Distribution of the severity index and observed and expected death rates in the validation cohort. The box plots indicate the observed mortality rates and their 95 % confidence intervals

The *c*-statistics for models 1, 2, 3, and 4 were 0.701 (95 % CI: 0.698, 0.705), 0.758 (95 % CI: 0.755, 0.761), 0.675 (95 % CI: 0.672, 0.679), and 0.767 (95 % CI: 0.764, 0.770), respectively. The IDI for the comparison of model 4 with model 3 was 0.0700 (95 % CI: 0.0682, 0.0719), representing improved discrimination in model 4. The *ω*-statistic in model 4 was 1.09 (95 % CI: 1.03, 1.17), representing a slightly larger contribution of the index compared with the other four variables combined. Model 4 was well-calibrated, as shown by the Hosmer--Lemeshow calibration plot presented in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Calibration plot of the model predicting in-hospital death in the validation cohort

The mortality rates and *c*-statistics of the subgroups of patients are presented in Table [4](#Tab4){ref-type="table"}. The model was well-calibrated for each diagnosis, as shown in Fig. [3](#Fig3){ref-type="fig"}. The model was also well-calibrated for other subgroups (data not shown).Table 4Results of subgroup analysesnMortality rate*c*-statistic95 % CIAdmission-precipitating diagnosis  Acute myocardial infarction10 1768.6 %0.8210.806 -- 0.836  Congestive heart failure56 9279.8 %0.7090.702 -- 0.716  Acute cerebrovascular disease90 0718.6 %0.8010.796 -- 0.807  Gastrointestinal hemorrhage34 4294.7 %0.7910.780 -- 0.801  Pneumonia68 38611.0 %0.7330.727 -- 0.739  Septicemia934222.4 %0.6990.686 -- 0.711Admission by ambulance  No166 9796.5 %0.7690.764 -- 0.773  Yes102 32714.3 %0.7440.740 -- 0.748Referral from another institution  No161 4949.9 %0.7690.766 -- 0.773  Yes107 8088.8 %0.7620.757 -- 0.767Hospital type  Non-academic225 4799.6 %0.7670.764 -- 0.770  Academic34 1628.3 %0.7590.749 -- 0.769CI -- confidence intervalFig. 3Calibration plots of models predicting in-hospital death in the validation cohort for six admissionprecipitating diagnoses (**a**, acute myocardial infarction; **b**, congestive heart failure; **c**, acute cerebrovascular disease; **d**, gastrointestinal hemorrhage; **e**, pneumonia; **f**, septicemia)

Discussion {#Sec11}
==========

Using the Diagnosis Procedure Combination nationwide administrative database of acute-care hospitals, we derived and internally validated a severity index for inpatients that utilizes procedure records to predict in-hospital death. In the patients with the six diseases examined, the index was widely distributed, and the model combining the severity index with age, sex, and CCI predicted in-hospital death well (*c*-statistic: 0.767).

We used procedures performed on the day of admission as indicators of severity on admission, and extracted 19 commonly performed procedures, diagnostic and therapeutic, that were significantly associated with in-hospital death or survival. The characteristics of the procedures differed widely, from routinely performed procedures (e.g. blood examinations) to those reflecting critically ill conditions (e.g. intratracheal intubation). This difference was represented in the weights given to each procedure, ranging from −3 to 23. The weights represented the strength of association between each procedure and death, relative to an increase in the CCI. The weighted numbers of the performed procedures were then summed into an index with a possible range of −13 to 69.

The mortality-predicting model with only diagnosis, age, sex, and CCI (model 3) had a fair discriminating ability (*c*-statistic: 0.675), and there was a significant improvement on the model performance when the severity index was added (IDI: 0.0700; *c*-statistic of model 4: 0.767). Furthermore, in model 4, the index contributed to the prediction of death more than all the other variables combined (*ω*-statistic: 1.09). These results represent the importance of the severity index for predicting mortality. To our knowledge, this is the first study to examine a mortality prediction model with commonly used procedures and medications, and the results suggest the usability of procedure records for risk adjustment.

Similar to other studies \[[@CR12], [@CR13]\], we chose six high-impact medical conditions (acute myocardial infarction, congestive heart failure, acute cerebrovascular disease, gastrointestinal hemorrhage, pneumonia, septicemia) as the target diseases. Although the single model had a good discriminating ability and was well-calibrated across various subgroups, the *c*-statistics ranged from 0.70 for septicemia to 0.82 for acute myocardial infarction. A previous study that used demographics, admission diagnosis, comorbidity-based score, and laboratory-based score as variables had similar results, in which the *c*-statistics were ≥0.80 for 29 admission diagnoses, 0.71--0.80 for 13 admission diagnoses, and \<0.70 for two admission diagnoses \[[@CR14]\]. Use of the same model for various primary illnesses may result in variable predictive ability across diagnoses because the effects of procedures on mortality may differ across diagnoses. In addition, the main diagnosis or main therapeutic procedure themselves are predictors of mortality \[[@CR14], [@CR15], [@CR20]\]. Therefore, care should be taken when comparing these results with models derived separately for different diagnoses, which often yield higher *c*-statistics \[[@CR12], [@CR13], [@CR16]--[@CR19]\].

Although comorbidities recorded in administrative databases have provided fairly good predictions of mortality, there have been concerns that diagnoses may reflect complications instead of comorbidities \[[@CR6]--[@CR10]\]. The use of numerical laboratory data is one method suggested by researchers, and high model *c*-statistics of \>0.8 were observed \[[@CR12]--[@CR16]\]. When available, laboratory data provide precise information about patient severity on admission and help to improve the model performance. However, implementation of an administrative database with laboratory data requires considerable cost and effort, and previous studies were thus confined to regional databases. In contrast, our study was conducted using a preexisting nationwide administrative database, and the procedures added considerable predictive ability to a model using demographics and comorbidities. The method presented here could be useful for similar databases with procedure data. For databases without procedure data, we recommend adding such data because it is relatively inexpensive and useful for mortality prediction.

Our study has several strengths. First, it was conducted using a nationwide database, and included patients of all ages treated in hospitals with different characteristics in all areas of Japan. Second, chronological information was considered in the diagnoses and procedures. We used the "admission-precipitating diagnosis" for case identification and the "comorbidities present on admission" for comorbidities. Similar to the use of "present on admission" codes in the previous US studies \[[@CR12], [@CR28]\] and "diagnosis-type indicator" codes in the previous Canadian studies \[[@CR9], [@CR29]\], our method prevents the misclassification of complications occurring during hospitalization as main diagnoses or comorbidities. Likewise, the information regarding dates of performance of procedures enabled the extraction of procedures performed on the day of admission. Third, we used the aspects of whether or not the procedures were performed as variables. Although procedure data are not as objective as automatically-recorded laboratory data, we believe that the validity of procedure data is higher than that of recorded diagnoses.

This study has several limitations. First, we only examined six medical conditions. It is unknown whether the severity index for inpatients developed in the present study is applicable to patients hospitalized for other conditions. Second, we excluded patients with critically ill conditions on the day of admission, because we expected that the associations of procedures with mortality would be different in these patients. Although some severe patients, such as intubated patients and those on catecholamines, were treated in general wards, as sometimes occurs in Japan \[[@CR30], [@CR31]\], and were thus included in the analysis, the issue of whether the index is valid for most critically ill patients, e.g. those admitted to the intensive care unit, requires further examination. Third, we limited the drugs to catecholamines and vasopressin, but other treatments such as intravenous fluids and antibiotics could also represent the severity on admission. Fourth, each admission was considered independent in the analyses. Better mortality prediction may be possible when clustering within patient and within site is taken into account. Also, the variance within each procedure, e.g., numbers or types of tested items within a blood test, was not accounted for. Last, the study was conducted in Japan using procedure codes in the Japanese fee reimbursement system, and the use of this index in other countries with different routine practices and coding systems will require appropriate conversions.

Conclusion {#Sec12}
==========

The newly developed severity index for inpatients using procedure records predicted in-hospital death well. Further validating research should lead to its application to risk adjustment.

Additional file {#Sec13}
===============

Additional file 1:**Procedures examined in the study.**
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